Article
Multidisciplinary Sciences
Sujin Kang, Jaekyung Kim, Areum Park, Minsoo Koh, Wonji Shin, Gayoung Park, Taeyun A. Lee, Hyung Jin Kim, Heonjong Han, Yongbo Kim, Myung Kyung Choi, Jae Hyung Park, Eunhye Lee, Hyun-Soo Cho, Hyun Woo Park, Jae Hee Cheon, Sungwook Lee, Boyoun Park
Summary: The authors found that TRIM40, an E3 ligase, disrupts cortical actin formation and leads to loss of epithelial barrier integrity. Genetic loss of TRIM40 is protective against experimental colitis in male mice.
NATURE COMMUNICATIONS
(2023)
Article
Plant Sciences
Huicun Zhang, Na Ta, Hong Shen, Hongbing Wang
Summary: JPQCHSD extract showed significant efficacy in treating TNBS-induced colitis in rats, with anti-inflammatory, immune regulation, and antioxidation properties. Further clinical trials are needed to confirm its effectiveness and safety in IBD treatment.
PHARMACEUTICAL BIOLOGY
(2021)
Review
Pharmacology & Pharmacy
Hajime Honjo, Tomohiro Watanabe, Ken Kamata, Kosuke Minaga, Masatoshi Kudo
Summary: Inflammatory bowel diseases (IBDs) are increasing worldwide, with many patients showing refractoriness to current treatments. Therefore, the search for novel therapeutic targets, such as RIPK2, is crucial. Experimental and clinical studies have implicated RIPK2 in the development of autoimmune diseases, particularly IBD, suggesting its potential as a new therapeutic target.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Gastroenterology & Hepatology
A. Swaminathan, G. M. Borichevsky, T. S. Edwards, E. Hirschfeld, T. C. Mules, C. M. Frampton, A. S. Day, M. B. Hampton, A. J. Kettle, R. B. Gearry
Summary: This study investigated the use of faecal myeloperoxidase (fMPO) as a biomarker for the activity of inflammatory bowel disease (IBD). The results showed that fMPO was significantly correlated with endoscopic activity and could accurately predict the severity and complexity of the disease.
JOURNAL OF CROHNS & COLITIS
(2022)
Article
Immunology
Ying Cao, Yibei Dai, Lingyu Zhang, Danhua Wang, Wen Hu, Qiao Yu, Xuchu Wang, Pan Yu, Weiwei Liu, Ying Ping, Tao Sun, Yiwen Sang, Zhenping Liu, Yan Chen, Zhihua Tao
Summary: The study demonstrates that in addition to fecal calprotectin, fecal Oncostatin M is a novel potential biomarker, and their combined use is more beneficial for the diagnosis of inflammatory bowel disease and prediction of infliximab therapeutic response. However, further research is needed for the evaluation of disease activity.
JOURNAL OF INFLAMMATION RESEARCH
(2021)
Article
Pediatrics
Manar Matar, Rachel Levi, Maya Zvuloni, Raanan Shamir, Amit Assa
Summary: This study aimed to assess the effect of anti-TNF alpha therapy on fecal calprotectin (FC) levels in children with inflammatory bowel disease (IBD). The results showed that the majority of patients achieved improvement in FC levels within a short period of time, but normalization of FC in responders required almost one year. The shorter the time from diagnosis to treatment, the faster the improvement in FC levels.
PEDIATRIC RESEARCH
(2023)
Article
Genetics & Heredity
Mohamad Karaky, Gabrielle Boucher, Sarai Mola, Sylvain Foisy, Claudine Beauchamp, Marie-Eve Rivard, Melanie Burnette, Hugues Gosselin, Alain Bitton, Guy Charron, Philippe Goyette, John D. Rioux
Summary: This study uncovers the role of PTGIR, PTGER4, ZBTB40, SLC39A11, and NFKB1 genes in inflammatory bowel disease (IBD), with all five genes regulating the expression of calprotectin (CP) in myeloid cells. The prostacyclin/prostaglandin biogenesis and signaling pathways may also play a potential role in IBD susceptibility and pathogenesis.
Article
Gastroenterology & Hepatology
Andreas Zollner, Andreas Schmiderer, Simon J. Reider, Georg Oberhuber, Alexandra Pfister, Bernhard Texler, Christina Watschinger, Robert Koch, Maria Effenberger, Tim Raine, Herbert Tilg, Alexander R. Moschen
Summary: This study demonstrated the diagnostic equivalence of FLCN2 and FCAL in inflammatory bowel diseases, with both biomarkers showing comparable sensitivity and specificity. Furthermore, mucosal overexpression of LCN2 in deep remission suggests its potential as a candidate for molecular inflammation warranting further investigation.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Gastroenterology & Hepatology
Takeo Naito, Gregory J. Botwin, Talin Haritunians, Dalin Li, Shaohong Yang, Michelle Khrom, Jonathan Braun, Lisa Abbou, Emebet Mengesha, Christine Stevens, Atsushi Masamune, Mark Daly, Dermot P. B. McGovern
Summary: Genetic factors play a significant role in the risk of thromboembolic disease (TED) in patients with inflammatory bowel disease (IBD). Patients with a high genetic TED risk are more likely to have thrombosis at multiple sites.
Article
Biochemistry & Molecular Biology
Olusegun G. Adebayo, Benneth Ben-Azu, Abayomi M. Ajayi, Iheanyichukwu Wopara, Wadioni Aduema, Tolunigba A. Kolawole, Elizabeth B. Umoren, Ijeoma Onyeleonu, Oloruntoba T. Ebo, Doris N. Ajibo, Ajirioghene E. Akpotu
Summary: The study found that GB-S significantly improved neurobehavioral impairments induced by lead, reduced MPO activity, inhibited TNF-alpha and IL-6 release, downregulated NF-kappa B expression, and prevented loss of pyramidal neurons in the hippocampus in mice.
BIOLOGICAL TRACE ELEMENT RESEARCH
(2022)
Article
Gastroenterology & Hepatology
Hirotaka Shimizu, Ryo Ebana, Takahiro Kudo, Takuro Sato, Tomoko Hara, Kenji Hosoi, Masaaki Usami, Masashi Yoshida, Ichiro Takeuchi, Hiroshi Nakase, Itaru Iwama, Katsuhiro Arai, Toshiaki Shimizu
Summary: Fecal calprotectin (FCP) and fecal immunochemical test (FIT) correlate well with endoscopic activity in pediatric patients with inflammatory bowel disease (IBD), and FCP is a superior marker for predicting mucosal healing (MH).
JOURNAL OF GASTROENTEROLOGY
(2022)
Review
Medicine, General & Internal
Jin-Tong Shi, Nuo Chen, Jia Xu, Hemant Goyal, Zhi-Qi Wu, Jie-Xin Zhang, Hua-Guo Xu
Summary: Fecal calprotectin (FC) levels are correlated with the disease activity of inflammatory bowel diseases (IBD), but its usefulness in predicting IBD relapse is yet to be determined. This study aimed to evaluate the efficacy of FC in predicting IBD relapse. A total of 24 prospective studies were included in the meta-analysis, and the optimal FC cut-off value was found to be 152 μg/g. The pooled sensitivity and specificity of FC were 0.720 (0.528 to 0.856) and 0.740 (0.618 to 0.834), respectively. FC is a valuable non-invasive and cost-effective biomarker for early prediction of IBD relapse, with an ideal threshold of 152 μg/g.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Immunology
Jagoda Pokryszka, Angelika Wagner, Ursula Wiedermann, Selma Tobudic, Harald Herkner, Stefan Winkler, Sonja Brehovsky, Walter Reinisch, Gottfried Novacek
Summary: This study assessed the mucosal inflammatory activity in IBD patients before and after vaccination with the mRNA-1273 (Moderna) vaccine. The results showed that vaccination can cause an increase in fCP levels in some patients, and vedolizumab was the only drug associated with this increase.
Article
Gastroenterology & Hepatology
Eelco C. Brand, Marjolein A. Y. Klaassen, Ranko Gacesa, Arnau Vich Vila, Hiren Ghosh, Marcel R. de Zoete, Dorret Boomsma, Frank Hoentjen, Carmen S. Horjus Talabur Horje, Paul C. van de Meeberg, Gonneke Willemsen, Jingyuan Fu, Cisca Wijmenga, Femke van Wijk, Alexandra Zhernakova, Bas Oldenburg, Rinse K. Weersma
Summary: The gut microbiome of healthy cotwins from IBD-discordant twin pairs displays IBD-like signatures, potentially preceding the onset of IBD. However, longitudinal follow-up studies are needed to infer a causal relationship.
Article
Gastroenterology & Hepatology
M. D. Voskuil, L. M. Spekhorst, K. W. J. van der Sloot, B. H. Jansen, G. Dijkstra, C. J. van der Woude, F. Hoentjen, M. J. Pierik, A. E. van der Meulen, N. K. H. de Boer, M. Lowenberg, B. Oldenburg, E. A. M. Festen, R. K. Weersma
Summary: IBD phenotypes show significant heterogeneity between patients, and genetic risk scores [GRS] can help unravel the genetic contributions to these phenotypes. The study findings indicate that different CD and UC GRS are associated with specific IBD phenotypes, driven mainly by genetic variation.
JOURNAL OF CROHNS & COLITIS
(2021)
Article
Gastroenterology & Hepatology
Anders Forss, Mark Clements, Par Myrelid, Hans Strid, Charlotte Soderman, Agnieszka Wagner, David Andersson, Fredrik Hjelm, Ola Olen, Jonas Halfvarson, Jonas F. Ludvigsson
Summary: This study demonstrates the long-term clinical effectiveness of ustekinumab in patients with active Crohn's disease, as well as its improvement in Health-related Quality of Life (HRQoL) measures.
DIGESTIVE DISEASES AND SCIENCES
(2023)
Article
Gastroenterology & Hepatology
Johanna Holmgren, Anna Froborg, Isabella Visuri, Jonas Halfvarson, Henrik Hjortswang, Pontus Karling, Par Myrelid, Ola Olen, Jonas F. Ludvigsson, Olof Grip
Summary: In patients with inflammatory bowel disease, the incidence rate of serious infection did not increase with the use of anti-TNF therapy and actually decreased more than 1 year after treatment initiation.
INFLAMMATORY BOWEL DISEASES
(2023)
Article
Gastroenterology & Hepatology
Laurent Peyrin-Biroulet, Jean-Francois Rahier, Julien Kirchgesner, Vered Abitbol, Sebastian Shaji, Alessandro Armuzzi, Konstantinos Karmiris, Javier P. Gisbert, Peter Bossuyt, Ulf Helwig, Johan Burisch, Henit Yanai, Glen A. Doherty, Fernando Magro, Tamas Molnar, Mark Lowenberg, Jonas Halfvarson, Edyta Zagorowicz, Helene Rousseau, Cedric Baumann, Filip Baert, Laurent Beaugerie
Summary: The I-CARE study aims to evaluate the benefit-risk ratio of current therapies in IBD patients. It collected data from 10,206 patients and observed the treatment risks of anti-tumor necrosis factor and other biologic therapies, particularly the risks of cancer/lymphoma and serious infections. The results showed that different treatment regimens had varying effects on patients, and further research is needed to assess specific risks.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY
(2023)
Article
Gastroenterology & Hepatology
Jie Chen, Yajing Zhou, Yuhao Sun, Shuai Yuan, Rahul Kalla, Jing Sun, Jianhui Zhao, Lijuan Wang, Xuejie Chen, Xuan Zhou, Siqi Dai, Yu Zhang, Gwo-tzer Ho, Dajing Xia, Qian Cao, Zhanju Liu, Susanna C. Larsson, Xiaoyan Wang, Kefeng Ding, Jonas Halfvarson, Xue Li, Evropi Theodoratou, Jack Satsangi
Summary: This study identified 14 proteins associated with the risk of ulcerative colitis (UC) through the analysis of serum proteomic profiling data. Further analysis using Mendelian randomisation confirmed the causal relationship between two chemokines and the increased risk of UC. Additionally, a new protein associated with UC risk was identified. Reverse Mendelian randomisation analysis did not find any influence of genetic predisposition to UC on these three inflammation proteins.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Edouard Louis, Matthieu Resche-Rigon, David Laharie, Jack Satsangi, Nik Ding, Britta Siegmund, Geert D'Haens, Laurence Picon, Peter Bossuyt, Lucine Vuitton, Peter Irving, Stephanie Viennot, Christopher A. Lamb, Richard Pollok, Filip Baert, Maria Nachury, Mathurin Fumery, Cyrielle Gilletta, Sven Almer, Shomron Ben-Horin, Yoram Bouhnik, Jean-Frederic Colombel, Erik Hertervig
Summary: This study aimed to compare the relapse rate and time in remission over 2 years between patients continuing combination therapy, stopping infliximab, or stopping immunosuppressant therapy for Crohn's disease. The results showed that stopping infliximab had a higher relapse rate compared to stopping immunosuppressant therapy, suggesting that stopping immunosuppressant therapy may be a preferable strategy for treatment de-escalation.
LANCET GASTROENTEROLOGY & HEPATOLOGY
(2023)
Article
Genetics & Heredity
Zhanju Liu, Ruize Liu, Han Gao, Seulgi Jung, Xiang Gao, Ruicong Sun, Xiaoming Liu, Yongjae Kim, Ho-Su Lee, Yosuke Kawai, Masao Nagasaki, Junji Umeno, Katsushi Tokunaga, Yoshitaka Kinouchi, Atsushi Masamune, Wenzhao Shi, Chengguo Shen, Zhenglin Guo, Kai Yuan, Shu Zhu, Dalin Li, Jianjun Liu, Tian Ge, Judy Cho, Mark J. Daly, Dermot P. B. McGovern, Byong Duk Ye, Kyuyoung Song, Yoichi Kakuta, Mingsong Li, Hailiang Huang, Maria Abreu, Jean-Paul Achkar, Vibeke Andersen, Charles Bernstein, Steven R. Brant, Luis Bujanda, Siew Chien Ng, Judy Cho, Mark J. Daly, Lee A. Denson, Richard H. Duerr, Lynnette R. Ferguson, Denis Franchimont, Andre Franke, Richard Gearry, Hakon Hakonarson, Jonas Halfvarson, Caren Heller, Hailiang Huang, Antonio Julia, Judith Kelsen, Hamed Khalili, Subramaniam Kugathasan, Juozas Kupcinskas, Anna Latiano, Edouard Louis, Reza Malekzadeh, Jacob L. McCauley, Dermot P. B. McGovern, Christopher Moran, David Okou, Tim Orchard, Aarno Palotie, Miles Parkes, Joel Pekow, Uros Potocnik, Graham Radford-Smith, John D. Rioux, Gerhard Rogler, Bruce Sands, Mark Silverberg, Harry Sokol, Severine Vermeire, Rinse K. Weersma, Ramnik J. Xavier, Naizhong Hu, Qian Cao, Yufang Wang, Yinglei Miao, Hongjie Zhang, Xiaoping Lv, Xiang Gao, Hu Zhang, Jingling Su, Baisui Feng, Ye Zhao, Liangru Zhu, Yan Chen, Lanxiang Zhu, Chunxiao Chen, Yali Wang, Yingde Wang, Zhi Pang, Yingxuan Chen, Xiaolan Zhang, Hui Li, Qin Yu, Mei Ye, Sumin Zhang, Wen Tang, Mei Wang, Xiaocang Cao, Ruixin Zhu, Guangxi Zhou, Zhaolian Bian, Xiaofeng Guo, Xiaoli Wu, Jinchun Liu, Wei Xu, Yuqin Li, Qin Guo, Zhiguo Guo, Mingsong Li, Zhanju Liu
Summary: This study provides the largest investigation of inflammatory bowel diseases (IBDs) in individuals of East Asian ancestries, identifying 80 IBD loci, including 81 new loci. The study also discovers new IBD genes, such as ADAP1 and GIT2, and improves the accuracy of predicting IBD risk by incorporating data from both East Asian and European ancestries.
Article
Medicine, General & Internal
Jiangwei Sun, Fang Fang, Ola Olen, Mingyang F. Song, Jonas Halfvarson, Bjorn Roelstraete, Hamed Khalili, Jonas Ludvigsson
Summary: In this study, individuals who underwent endoscopic biopsy with normal mucosa were followed up for a median of 10 years. The study found that these individuals had an elevated risk of inflammatory bowel disease (IBD) for at least 30 years. These findings imply the presence of a substantial symptomatic period before the diagnosis of IBD and emphasize the importance of considering the long-term risk of IBD in patients with symptoms but normal mucosa on gastrointestinal investigation.
Article
Gastroenterology & Hepatology
Aiva Lundberg Bave, Ola Olen, Jonas Soederling, Jonas F. Ludvigsson, Annika Bergquist, Caroline Nordenvall
Summary: Colectomy in UC patients was not associated with a decreased risk of subsequent PSC. The observed differences in the risk of PSC development over calendar periods are likely due to changes in PSC-diagnosis and UC-treatment.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2023)
Article
Gastroenterology & Hepatology
Jamie M. Horrigan, Edouard Louis, Antonino Spinelli, Simon Travis, Bjorn Moum, Jessica Salwen-Deremer, Jonas Halfvarson, Remo Panaccione, Marla C. Dubinsky, Pia Munkholm, Corey A. Siegel
Summary: This study investigated the global use and barriers to using patient-reported outcomes (PROs) in clinical practice for inflammatory bowel disease (IBD). The majority of healthcare providers use PROs in clinical practice, but there are variations in which PROs are used and how they influence management. Barriers to using PROs include lack of familiarity, integration issues, and time constraints. Education about PROs and the use of an accepted set of PROs can help overcome these barriers and achieve global harmonization.
CROHNS & COLITIS 360
(2023)
Article
Gastroenterology & Hepatology
Joel Thunberg, Olle Granno, Daniel Bergemalm, Carl Eriksson, Isabella Visuri, Michael Eberhardson, Jonas Halfvarson
Summary: This study examined the agreement between a point-of-care test (POCT) by ProciseDx and the in-house enzyme-linked immunosorbent assay (ELISA) for infliximab (IFX) quantification. The results showed good agreement between the two methods, supporting the use of ProciseDx's POCT for rapid IFX quantification.
SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY
(2023)
Article
Medicine, General & Internal
Jiangwei Sun, Bjorn Roelstraete, Emma Svennberg, Jonas Halfvarson, Johan Sundstrom, Anders Forss, Ola Olen, Jonas F. Ludvigsson
Summary: This study found that patients with inflammatory bowel disease (IBD) have an increased risk of developing arrhythmias. This increased risk persists even 25 years after the diagnosis of IBD.
Article
Medicine, General & Internal
Ferdinando D'Amico, Virginia Solitano, Fernando Magro, Pablo A. Olivera, Jonas Halfvarson, David Rubin, Axel Dignass, Sameer Al Awadhi, Taku Kobayashi, Natalia Sousa Freitas Queiroz, Marta Calvo, Paulo Gustavo Kotze, Subrata Ghosh, Laurent Peyrin-Biroulet, Silvio Danese
Summary: As the patents for biologic originator drugs expire, biosimilars are emerging as cost-effective alternatives within healthcare systems. A global survey was conducted to shed light on physicians' knowledge, beliefs, practical approaches, and concerns related to biosimilar adoption. Based on the survey results, a consensus was reached on key statements covering biosimilar effectiveness, safety, indications, rationale, multiple switches, therapeutic drug monitoring, non-medical switching, and future perspectives. The consensus affirmed that biosimilars are equally effective and safe compared to originator drugs.
JOURNAL OF CLINICAL MEDICINE
(2023)
Article
Gastroenterology & Hepatology
Isabella Visuri, Carl Eriksson, Sara Karlqvist, Byron Lykiardopoulos, Per Karlen, Olof Grip, Charlotte Soderman, Sven Almer, Erik Hertervig, Jan Marsal, Carolina Malmgren, Jenny Delin, Hans Strid, Mats Sjoberg, Daniel Bergemalm, Henrik Hjortswang, Jonas Halfvarson
Summary: This study assessed the long-term outcomes of vedolizumab in treating inflammatory bowel disease. The results showed that vedolizumab had high continuation rates and was associated with improvements in clinical outcomes, health-related quality of life measures, and inflammatory markers at 2 and 3 years after treatment initiation.
THERAPEUTIC ADVANCES IN GASTROENTEROLOGY
(2023)
Article
Gastroenterology & Hepatology
Archana Shubhakar, Bas C. Jansen, Alex T. Adams, Karli R. Reiding, Nicholas T. Ventham, Rahul Kalla, Daniel Bergemalm, Paulina A. Urbanowicz, Richard A. Gardner, Manfred IBD BIOM Consortium, Manfred Wuhrer, Jonas Halfvarson, Jack Satsangi, Daryl L. Fernandes, Daniel I. R. Spencer
Summary: This study investigated a composite serum N-glycomic biomarker to predict future disease course in newly diagnosed IBD patients. The biomarker showed a predictive capacity for treatment escalation in both the discovery and replication cohorts of patients.
JOURNAL OF CROHNS & COLITIS
(2023)
Article
Gastroenterology & Hepatology
Amiko M. Uchida, John J. Garber, Ashley Pyne, Kathryn Peterson, Bjorn Roelstraete, Ola Olen, Jonas Halfvarson, Jonas F. Ludvigsson
Summary: In this nationwide cohort study, EoE was found to be associated with a 3.5-fold increased risk of later IBD diagnosis, possibly due to genetic or early environmental risk factors.
UNITED EUROPEAN GASTROENTEROLOGY JOURNAL
(2023)